Description
Aerie Pharmaceuticals, Inc. is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidate, AR-13324, is a dual-action drug class. AR-13324 is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. It acts through the inhibition of both Rho Kinase (ROCK) and the Norepinephrine Transporter (NET). Its dual-action product has completed phase-II development. The Company’s product candidate PG324 is a fixed combination of dual-action AR-13324 with latanoprost formulated in a single eye drop and is designed to intraocular pressure by reducing fluid inflow while also opening both of the eye’s fluid drains.
Address
Suite 15, 135 US Highway 206
BEDMINSTER, NJ 92660
United States
BEDMINSTER, NJ 92660
United States
Website
www.aeriepharma.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | - | -160.39% |
| Return on average equity | - | - |
| Employees | 23 |
No comments:
Post a Comment